Cibc World Market Inc. Takes Position in United Therapeutics Corporation $UTHR

Cibc World Market Inc. purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,419 shares of the biotechnology company’s stock, valued at approximately $769,000.

Other hedge funds have also recently made changes to their positions in the company. Torren Management LLC purchased a new stake in United Therapeutics in the fourth quarter worth approximately $26,000. Activest Wealth Management raised its stake in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC purchased a new stake in United Therapeutics during the 4th quarter valued at $31,000. International Assets Investment Management LLC lifted its holdings in shares of United Therapeutics by 426.7% during the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB lifted its holdings in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $23,631,280.08. The trade was a 15.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $517.28, for a total value of $4,914,160.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $167,827,875.04. This trade represents a 2.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 424,075 shares of company stock valued at $227,336,485 in the last three months. 8.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on UTHR. Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Royal Bank Of Canada dropped their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. JPMorgan Chase & Co. upped their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Price Performance

Shares of UTHR stock opened at $527.91 on Friday. The company has a market cap of $22.64 billion, a price-to-earnings ratio of 18.89, a PEG ratio of 1.75 and a beta of 0.59. United Therapeutics Corporation has a 1 year low of $302.19 and a 1 year high of $609.35. The firm has a fifty day moving average price of $530.89 and a 200-day moving average price of $538.86.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.United Therapeutics’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the firm earned $6.41 EPS. Equities research analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.